Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- GSK Keeps Its JCR Stake at 25%, Eyes Collaboration in Blood-Brain Barrier Technology
April 4, 2016
- Asahi Kasei Pharma Licenses TrkA Inhibitors from Array BioPharma
April 4, 2016
- Meiji Seika Pharma Gets Rights to Distribute Ultibro, Seebri in Japan; Novartis to Continue Copromotion
April 4, 2016
- Astellas Completes Transfer of Dermatology Biz to LEO Pharma
April 4, 2016
- Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
April 4, 2016
- Nichi-Iko Gets Global Rights to Rituximab Biosimilar from S. Korea’s Aprogen
April 4, 2016
- Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
- Daiichi Sankyo Files NDA for Hydromorphone, Standard Pain Therapy Outside Japan
April 1, 2016
- Towa Prevails in Patent Suit over Elplat
April 1, 2016
- Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
April 1, 2016
- Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
April 1, 2016
- Eisai Gives Rights for Cancer Drug to Dr. Reddy’s Outside Japan, Asia
April 1, 2016
- Gilead Files Japan NDA for Tenofovir Prodrug for Chronic Hep B
April 1, 2016
- Janssen Seeks MCL Indication for Imbruvica
April 1, 2016
- HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
March 31, 2016
- Eisai Transfers Thrombocytopenia Drug to US Investment Firm
March 31, 2016
- Janssen Files Stelara for Crohn’s Disease
March 31, 2016
- EA Pharma to Start Up with 440 Sales Reps, Offer 24 Products
March 31, 2016
- Kyorin, Kissei to Jointly Develop, Market OAB Treatment
March 31, 2016
- Santen Gets Worldwide Rights to Ono’s FP and EP3 Dual Receptor Agonist
March 31, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…